Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Chi-Yung Shang"'
Autor:
Huey-Ling Chiang, Hsiang-Yuan Lin, Wen-Yih Isaac Tseng, Shoou-Lian Hwang-Gu, Chi-Yung Shang, Susan Shur-Fen Gau
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 2, Pp 546-556 (2022)
Background/purpose: Increased intra-individual variability (IIV) in reaction time (RT) is a key feature of attention-deficit/hyperactivity disorder (ADHD). However, little is known about neurobiology underpinnings of IIV in ADHD. Methods: We assessed
Externí odkaz:
https://doaj.org/article/e8f4d0a6a9544c53adb2b42ae0eeb265
Autor:
Wen-Yih Isaac Tseng, Huey-Ling Chiang, Hsiang-Yuan Lin, Susan Shur-Fen Gau, Chi-Yung Shang, Shoou-Lian Hwang-Gu
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 2, Pp 546-556 (2022)
Background/purpose Increased intra-individual variability (IIV) in reaction time (RT) is a key feature of attention-deficit/hyperactivity disorder (ADHD). However, little is known about neurobiology underpinnings of IIV in ADHD. Methods We assessed 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f9feb58948859d28e6f27eb7b73b5ff
https://doi.org/10.1016/j.jfma.2021.06.003
https://doi.org/10.1016/j.jfma.2021.06.003
Publikováno v:
Journal of child and adolescent psychopharmacology. 32(9)
biObjective:/i/bMethylphenidate is effective in reducing the clinical symptoms of patients with attention-deficit/hyperactivity disorder (ADHD). ORADURsup®/sup-methylphenidate is a new extended-release preparation of methylphenidate. This study aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3e33c871d5541e57625c175570e3c5
https://pubmed.ncbi.nlm.nih.gov/36251766
https://pubmed.ncbi.nlm.nih.gov/36251766
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 31:187-196
Objectives: This study aimed to compare the efficacy of methylphenidate and atomoxetine on improving executive functions among children with attention-deficit/hyperactivity disorder (ADHD). Methods...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddcf7c7c415fc658e390a327f4f1d0ad
https://doi.org/10.1089/cap.2020.0146
https://doi.org/10.1089/cap.2020.0146
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objective: Methylphenidate (MPH) is efficacious in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD), but there are no data about the efficacy and safety of its new formulation (ORADUR®-MPH extended release, ORADUR-MPH) in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a889a0bf2029c3439ff675f873cf41
http://europepmc.org/articles/PMC8066345
http://europepmc.org/articles/PMC8066345
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 30:148-158
Objective: Although methylphenidate and atomoxetine have positive effects in reducing core symptoms and emotional/behavioral problems of attention-deficit/hyperactivity disorder (ADHD), little is k...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087dd303bd440b00e4e0a35e9fca12df
https://doi.org/10.1089/cap.2019.0139
https://doi.org/10.1089/cap.2019.0139
Publikováno v:
Journal of Child and Adolescent Psychopharmacology. 29:9-19
Methylphenidate and atomoxetine are efficacious in reducing core symptoms of attention-deficit/hyperactivity disorder (ADHD), but little is known about their efficacy in improving emotional/behavioral problems among youths with ADHD.One hundred sixty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c84e51cac139114e97aaf0ad7309fe9
https://doi.org/10.1089/cap.2018.0076
https://doi.org/10.1089/cap.2018.0076
Autor:
Wen-Yih Isaac Tseng, Chi-Yung Shang, Hsiang-Yuan Lin, Susan Shur-Fen Gau, Yu-Hung Tung, Yung-Chin Hsu, Li-Ying Yang, Chang-Le Chen
Publikováno v:
The American journal of psychiatry. 178(8)
The heterogeneity of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) preclude definitive identification of neurobiomarkers and biological risks. High clinical overlap suggests multifaceted circuit-level alterations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105bd5fe480cf3c8362db15ec273730f
https://pubmed.ncbi.nlm.nih.gov/33726525
https://pubmed.ncbi.nlm.nih.gov/33726525
Autor:
Yi-Ling Chien, Hsiang-Yuan Lin, Yu-Hung Tung, Tzung-Jeng Hwang, Chang-Le Chen, Chi-Shin Wu, Chi-Yung Shang, Hai-Gwo Hwu, Wen-Yih Isaac Tseng, Chih-Min Liu, Susan Shur-Fen Gau
Publikováno v:
Molecular psychiatry. 27(8)
The neurodevelopmental model of schizophrenia is supported by multi-level impairments shared among schizophrenia and neurodevelopmental disorders. Despite schizophrenia and typical neurodevelopmental disorders, i.e., autism spectrum disorder (ASD) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3df5b6939a3033a77e727064b12b4aa
https://pubmed.ncbi.nlm.nih.gov/35794186
https://pubmed.ncbi.nlm.nih.gov/35794186
Publikováno v:
Psychological Medicine. 48:2530-2540
BackgroundThe dopamine transporter gene (DAT1) and visual memory deficits have been consistently reported to be associated with attention-deficit/hyperactivity disorder (ADHD). This study aimed to examine whether a DAT1 haplotype affected functional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1beb3a8a52aeae3be9673422ee53b162
https://doi.org/10.1017/s0033291718000144
https://doi.org/10.1017/s0033291718000144